Emerging antibiotics for community-acquired pneumonia
Adamantia Liapikou1, Catia Cilloniz2, Andrea Palomeque2
16st Respiratory Department, Sotiria Hospital, Athens, Greece.
Expert Opinion on Emerging Drugs
|October 29, 2019
Summary
New antibiotics like ceftaroline and omadacycline offer improved treatment for community-acquired pneumonia (CAP). Emerging drugs show promise in combating antibiotic resistance in CAP bacterial infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Trials
Background:
- Community-acquired pneumonia (CAP) is a leading cause of hospitalization and mortality, particularly in the elderly.
- Rising antibiotic resistance in key pathogens like Streptococcus pneumoniae necessitates novel therapeutic strategies.
- Empirical treatment of CAP is becoming increasingly challenging due to resistance patterns.
Purpose of the Study:
- To summarize recently approved and emerging antibiotic treatments for community-acquired pneumonia.
- To review phase III clinical trials of antibiotic therapies for CAP from 2000-2019.
- To highlight potential improvements in empirical CAP treatment.
Main Methods:
- Systematic search of PubMed and ClinicalTrials.gov for relevant English-language phase III clinical trials.
- Inclusion of trials conducted between 2000 and 2019.
- Focus on antibiotic treatments for community-acquired pneumonia.
Main Results:
- Ceftaroline (cephalosporin) and omadacycline (cycline) are FDA-approved for CAP treatment.
- Lefamulin (pleuromutilin) is in phase III development.
- Other agents studied include solithromycin, nemonoxacin, delafloxacin, and zabofloxacin.
Conclusions:
- New antibiotics offer improved options for CAP management.
- Emerging therapies may help overcome challenges posed by antibiotic resistance.
- Continued research and development are crucial for effective CAP treatment.
More Related Videos
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
27.4K
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
7.5K
Related Concept Videos
01:28Pneumonia IV: Management
708
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
708
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
253
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
253
01:30Pneumonia I: Introduction
675
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
675
01:30Pneumonia III: Complications and Assessment
744
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
744
01:27Combined Effects of Drugs: Synergism
6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.7K
01:30Pneumonia V: Nursing management and Prevention
3.3K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.3K